Evidence map›Paper›PMID 35141142›Full record

ArticleFrontiers in oncology2021

Association Between Tumor Mutation Profile and Clinical Outcomes Among Hispanic-Latino Patients With Metastatic Colorectal Cancer.

Alexander Philipovskiy, Reshad Ghafouri, Alok Kumar Dwivedi, Luis Alvarado, Richard McCallum, Felipe Maegawa, Ioannis T Konstantinidis, Nawar Hakim, Scott Shurmur, Sanjay Awasthi and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Impact ofCancers · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Alexander PhilipovskiyDepartment of Internal Medicine, Division of Hematology-Oncology, Texas Tech University Health Sciences Center Lubbock, Lubbock, TX, United States.
Reshad GhafouriDepartment of Internal Medicine, Division of Hematology-Oncology, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Alok Kumar DwivediDepartment of Molecular and Translational Medicine, Division of Biostatistics & Epidemiology, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Luis AlvaradoDepartment of Molecular and Translational Medicine, Division of Biostatistics & Epidemiology, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Richard McCallumDepartment of Internal Medicine, Division of Gastroenterology, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Felipe MaegawaDepartment of Surgery, Southern Arizona VA Health Care System, University of Arizona, Tucson, AZ, United States.
Ioannis T KonstantinidisDepartment of Surgery, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Nawar HakimDepartment of Pathology, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Scott ShurmurDepartment of Internal Medicine, Division of Hematology-Oncology, Texas Tech University Health Sciences Center Lubbock, Lubbock, TX, United States.
Sanjay AwasthiDepartment of Internal Medicine, Division of Hematology-Oncology, Texas Tech University Health Sciences Center Lubbock, Lubbock, TX, United States.
Sumit GaurDepartment of Internal Medicine, Division of Hematology-Oncology, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Javier CorralDepartment of Internal Medicine, Division of Hematology-Oncology, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United States.
Texas Tech University Health Sciences Center · USTexas Tech University · USUniversity of Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the United States, CRC is the third most common type of cancer and the second leading cause of cancer-related death. Although the incidence of CRC among the Hispanic population has been declining, recently, a dramatic increase in CRC incidents among HL younger than 50 years of age has been reported. The incidence of early-onset CRC is more significant in HL population (45%) than in non-Hispanic Whites (27%) and African-Americans (15%). The reason for these racial disparities and the biology of CRC in the HL are not well understood. We performed this study to understand the biology of the disease in HL patients. We analyzed formalin-fixed paraffin-embedded tumor tissue samples from 52 HL patients with mCRC. We compared the results with individual patient clinical histories and outcomes. We identified commonly altered genes in HL patients (

Indexed as

APCcolon cancerGnasHispanic-Latino patientsKRASNOTCHTP53tumor mutation profile

Identifiers

PMID35141142
PMCPMC8819001
OpenAlexW4226190168

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.